The relative amount of apolipoprotein (apo-) E mRNA in 12 different tissues of the rat and marmoset was examined by dot blot hybridization using cloned cDNA probes. As expected, it was found to be most abundant in the liver. However, substantial amounts of apo-E mRNA were found in the brain and adrenals at relative levels about one-third of that found in the liver. Significant quantities of apo-E mRNA were detected in all of the other peripheral tissues as well. The apo-E mRNA levels in these tissues were 2-10% of that found in the liver of the rat and 10-30% of that found in the liver of the marmoset. Apo-E mRNA was also abundant in human brain and in each species examined; it was distributed throughout all major areas of this organ. In contrast, apo-A-I mRNA was detected in abundant amounts only in the small intestine and in the liver. Extrahepatic apo-E mRNA appears to be functional, generating a translation product similar or identical to that generated by the liver. During fetal and neonatal development, apo-E mRNA is rapidly induced from low levels to -60% of adult levels in liver at parturition. The fetal yolk sac contains more apo-E mRNA than the fetal liver, suggesting a significant role for the yolk sac as a source of apo-E during gestation.
Apolipoprotein (apo-) E is a constituent of various plasma lipoproteins in all mammals that have been examined (for review, see refs. 1 and 2). It is a single-chain polypeptide of Mr 34,000, whose complete amino acid sequence is known for the human (3) and rat (4) proteins.
Apo-E is important in the metabolism of cholesterol and other lipids. Of major significance is its role in mediating the interaction of specific lipoproteins with extrahepatic and hepatic apo-B,E(low density lipoprotein) [apo-B,E(LDL)] receptors and the unique hepatic apo-E receptors (for review, see ref. 5 ). Recent studies have localized the receptor binding domain of apo-E to a unique arginine-and lysine-enriched region of the molecule in the vicinity of residues 140-160 (6, 7) . Variant forms of apo-E that display defective receptor binding activity have been shown to have single amino acid substitutions in this region of the molecule (8) (9) (10) . These receptor-defective variants are associated with type III hyperlipoproteinemia. This disease is caused, in part, by the occurrence of the defective apo-E, which results in the accumulation of cholesterol-rich lipoproteins in the plasma of affected subjects and leads to accelerated cardiovascular disease (for review, see refs. 11 and 12).
The major site for apo-E synthesis is in the liver (for review, see ref. 13 ). The mRNA encoding apo-E has been reported to represent -1.0% of the total mRNA in the rat liver (14) . Apo-E is also one of the major proteins synthesized and secreted by mouse peritoneal macrophages and by macrophages derived from human monocytes (15) . Furthermore, low levels of apo-E synthesis have been detected in a limited number of peripheral tissues, including the adrenals and kidneys of man (16) , monkeys (17) , mice (18) , and guinea pigs (19) . A trace amount of apo-E synthesis was measured in the rat intestine (4) . To assess the potential of a wide variety of tissues to produce apo-E, this study has examined the relative distribution of apo-E mRNA in 12 tissues of both rats and marmosets. The results are compared to those gathered in the analysis of apo-A-I mRNA distribution in these same tissues. Apo-A-I is also important in the metabolism of circulating lipids. It is a Mr 28,000 constituent of several lipoproteins and functions as an activator of lecithin:cholesterol acyltransferase (13) . Knowledge of the expression of these apolipoprotein mRNAs in peripheral tissues should facilitate our understanding of their metabolic roles.
EXPERIMENTAL PROCEDURES Animals. All rats employed were of the Sprague-Dawley strain. Normal male rats weighing either 120-140 or 190-210 g were obtained from Charles River Breeding Laboratories (Wilmington, MA) or Simonsen Laboratories (Gilroy, CA). They were allowed free access to Purina Rat Chow. All rats were housed under a controlled temperature and humidity environment with a 12-hr light cycle. Timed-pregnant rats were obtained from Charles River for the collection of fetal, neonatal, and maternal tissues. Normal adult male marmosets of about 450 g were obtained from South American Primates (Miami, FL) and were maintained under controlled laboratory conditions for at least 3 months before use. Marmosets were fed the Hills Zu-preen Marmoset Diet supplemented with Hi-Pro Monkey Biscuits and fruit.
RNA Preparation and Analysis. Total cellular RNA was extracted from pulverized frozen tissues by guanidine thiocyanate and sedimentation through a cesium chloride cushion essentially according to Chirgwin et al. (20) . Total cellular RNA was examined for apo-E mRNA translational activity using cell-free translation, immunoprecipitation with a specific apo-E polyclonal antibody, gel electrophoresis, and fluorography, as described (4) . Size analysis of apo-E mRNA using gel-filter blot hybridization was performed essentially according to Thomas (21) as described (4) . All RNA blots were hybridized to 32P-labeled recombinant plasmids containing specific cDNA inserts corresponding to an individual mRNA species. Plasmid DNA was labeled by nick- 
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The possibility that apo-E gene expression might be regulated differently in the liver and extrahepatic tissues and that this knowledge might provide insights into the function of apo-E in the various tissues was investigated by measuring apo-E mRNA levels during development. Several tissues from fetal and neonatal rats were studied to determine relative amounts of apo-E mRNA. Fig. 5 shows that the fetal liver examined contained relatively low levels of apo-E mRNA until just prior to parturition, at which time there was a rapid induction from low levels to =60% of adult levels in the neonate. In comparison, brain apo-E mRNA levels were relatively low in the neonate, rising gradually to adult levels. Kidney and spleen apo-E mRNA showed a different developmental pattern, with neonatal levels slightly higher than adult levels. No apo-E mRNA was detected in fetal or neonatal intestine (data not shown). Apo-E mRNA levels in maternal liver were altered over a 2-fold range during the time just prior to and following parturition, suggesting that apo-E gene expression was affected by the hormonal alterations that occurred in the maternal animal at this time. Of particular interest was the substantial amount of apo-E mRNA found in the yolk sac during fetal development, with levels much higher than that found in the liver early in gestation (Fig. 5) . No apo-E was found in the placenta during this time (data not shown).
DISCUSSION
The presence of relatively large amounts of apo-E mRNA in the brain, in the adrenals, and in various other tissues in ad- FIG. 4 . Translation of total mRNA from different marmoset tissues. Total cellular RNA was translated in a cell-free system. Portions of the total translation products from the mRNA of each tissue were immunoprecipitated with antibody to human apo-E. Total translation products were electrophoresed in 12% polyacrylamide gels so that immunoprecipitation products could be clearly detected. For each tissue, total translation products and the corresponding apo-E immunoprecipitate (Immpt.) are shown. Antibodies were prepared against apo-E that had been purified from plasma very low density lipoproteins (VLDL); they were demonstrated to be monospecific by immunoassay (26) . (27) . In support of this finding, slices of rat brain have been shown to secrete immunoprecipitable apo-E (28).
Because apo-E is known to be produced by macrophages (29) , and because it is subject to suppression by bacterial endotoxins (30) , consideration was given to the possibility that apo-E might be the product of resident tissue macrophages or macrophage-like cells. The differences seen in the levels of apo-E mRNA in such tissues as the lung, spleen, and adrenals may reflect the level of activation of resident macrophages. Furthermore, the differences described in the Sprague-Dawley rats (Fig. 1) The development induction of apo-E mRNA in the liver and other fetal and neonatal tissues is striking. The rapid increase of apo-E mRNA in the liver at parturition may be in response to hormonal regulation, feeding (suckling), or the loss of apo-E production by the yolk sac. It appears that the apo-E gene in the neonate is expressed somewhat differently in the various extrahepatic tissues in comparison to the liver during development. The detection of relatively large amounts of apo-E mRNA in the yolk sac, a tissue of fetal origin having some characteristics in common with the liver and small intestine (32) , is also of particular interest. Because the yield of total poly(A)-containing RNA from the yolk sac is about the same as that of the fetal liver (33), it seems likely that the fetus derives most of its apo-E during development from the yolk sac.
The physiological basis for the production of apo-E by extrahepatic tissues is unclear. One possible function suggested by the known physiology of this protein is that the apo-E produced by peripheral tissues may participate in cholesterol redistribution among cells. Apo-E mediates the binding of lipoproteins to apo-B,E(LDL) receptors and readily associates with various lipoproteins, including high density lipoproteins (HDL). As HDL accept cholesterol from cells, and as their cholesterol content increases, apo-E becomes associated with these particles to form HDL-with apo-E (34) . Therefore, by virtue of the presence of apo-E, HDL may mediate cholesterol homeostasis in the local tissue environment. Thus, local production of apo-E may facilitate this overall process. Taking into consideration the yield of total RNA as well as the relative content of apo-E mRNA in extrahepatic tissues, about 10% of rat and about 20%o of marmoset apo-E in the circulation could be derived from these tissues.
Thepotential importance of apo-E synthesis in the brain is unknown. However, brain apo-E may be involved in the transportation of cholesterol and other lipids (such as essential fatty acids from the diet) to or from the cells that are behind the blood-brain barrier within the relatively isolated compartment of the brain. It has been reported that apo-E is present in high concentrations in the cerebrospinal fluid (3-5% of the plasma level compared to 0.5% of the plasma concentration for apo-A-I) and that this apo-E floats as a lipoprotein complex (35) . In addition to the potential role for apo-E in transporting cholesterol and lipids within the interstitial fluid of the brain, it may have alternate roles in the brain, as a structural protein, a neurotransmitter, or a neurohormone precursor. Further studies are required to elucidate the function of apo-E within the brain.
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